Ursodeoxycholic acid inhibits endothelin-1 production in human vascular endothelial cells

European Journal of Pharmacology

Volumn 505, Issue 1-3, 2004, Pages 67-74

  Ma, Ji ^a,b   Iida, Haruko ^a   Jo, Taisuke ^a   Takano, Haruhito ^a   Oonuma, Hitoshi ^a   Morita, Toshihiro ^a   Toyo Oka, Teruhiko ^a   Omata, Masao ^a   Nagai, Ryozo ^a   Okuda, Yukichi ^b   Yamada, Nobuhiro ^b   Nakajima, Toshiaki ^a,c  

^a Univ T   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

Endothelin 1; Human endothelial cell; Nitric oxide; Real time RT PCR; Ursodeoxycholic acid

Indexed keywords

ENDOTHELIN 1; GLYCOURSODEOXYCHOLIC ACID; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; SODIUM CHLORIDE; TAUROSODEOXYCHOLIC ACID; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

ARTICLE; CELL CULTURE; CELL SECRETION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG CONJUGATION; DRUG EFFECT; DRUG POTENCY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN SECRETION; TECHNIQUE; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ENDOTHELIN-1; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMANS; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; URSODEOXYCHOLIC ACID;

EID: 8844234954     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2004.10.042     Document Type: Article

References (41)

1. I. Alam, N.M. Bass, P. Bacchetti, L. Gee, and D.C. Rockey Hepatic tissue endothelin-1 levels in chronic liver disease correlate with disease severity and ascites Am. J. Gastroenterol. 95 2000 199 203
2. M. Bernardi, V. Gulberg, A. Colantoni, F. Trevisani, A. Gasbarrini, and A.L. Gerbes Plasma endothelin-1 and -3 in cirrhosis: relationship with systemic hemodynamics, renal function and neurohumoral systems J. Hepatol. 24 1996 161 168
3. C.M. Bruno, S. Neri, C. Sciacca, and L. Caruso Plasma endothelin-1 levels in liver cirrhosis Int. J. Clin. Lab. Res. 30 2000 169 172
4. W.B. Cao, Z.P. Zeng, Y.J. Zhu, W.C. Luo, and B.Q. Cai Inhibition of nitric oxide synthesis increases the secretion of endothelin-1 in vivo and in cultured endothelial cells Chin. Med. J. (Engl.) 107 1994 822 826
5. K. Chisaki, T. Nakajima, K. Iwasawa, H. Iida, A. Matsumoto, M. Tada, Y. Komatsu, K. Hirose, K. Miyamoto, Y. Okuda, Y. Shiratori, A. Goto, Y. Hirata, R. Nagai, and M. Omata Enhancement of endothelial nitric oxide production by chenodeoxycholic acids in patients with hepatobiliary diseases Jpn. Heart J. 42 2001 339 353
6. N.W. Cirillo, and R.F. Zwas Ursodeoxycholic acid in the treatment of chronic liver disease Am. J. Gastroenterol. 89 1994 1447 1452
7. S. Fiorucci, E. Antonelli, O. Morelli, A. Mencarelli, A. Casini, T. Mello, B. Palazzetti, D. Tallet, P. del Soldato, and A. Morelli NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension Proc. Natl. Acad. Sci. U. S. A. 98 2001 8897 8902
8. C.R. Gandhi, K. Stephenson, and M.S. Olson Endothelin, a potent peptide agonist in the liver J. Biol. Chem. 265 1990 17432 17435
9. C.M. Garner, C.O. Mills, E. Elias, and J.M. Neuberger The effect of bile salts on human vascular endothelial cells Biochim. Biophys. Acta 1091 1991 41 45
10. M. Horie, S. Uchida, M. Yanagisawa, Y. Matsushita, K. Kurokawa, and E. Ogata Mechanisms of endothelin-1 mRNA and peptides induction by TGF-beta and TPA in MDCK cells J. Cardiovasc. Pharmacol. 17 Suppl. 7 1991 S222 S225
11. R.M. Hu, E.R. Levin, A. Pedram, and H.J. Frank Atrial natriuretic peptide inhibits the production and secretion of endothelin from cultured endothelial cells. Mediation through the C-receptor J. Biol. Chem. 267 1992 17384 17389
12. A. Inoue, M. Yanagisawa, Y. Takuwa, Y. Mitsui, M. Kobayashi, and T. Masaki The human preproendothelin-1 gene. Complete nucleotide sequence and regulation of expression J. Biol. Chem. 264 1989 14954 14959
13. C.M. Isales, M.H. Nathanson, and R. Bruck Endothelin-1 induces cholestasis which is mediated by an increase in portal pressure Biochem. Biophys. Res. Commun. 191 1993 1244 1251
14. T. Jo, T. Nagata, H. Iida, H. Imuta, K. Iwasawa, J. Ma, K. Hara, M. Omata, R. Nagai, H. Takizawa, T. Nagase, and T. Nakajima Voltage-gated sodium channel expressed in cultured human smooth muscle cells: involvement of SCN9A FEBS Lett. 567 2004 339 343
15. Y. Kita, H. Sakakura, M. Hirata, Y. Harihara, H. Tanaka, M. Ito, H. Yoshino, T. Takayama, K. Kubota, K. Hashizume, and M. Makuuchi Ursodeoxycholic acid in serum and liver tissue in patients with end-stage cholestatic liver cirrhosis Transplant. Proc. 31 1999 2897 2898
16. R.H. Kuddus, M.A. Nalesnik, V.M. Subbotin, A.S. Rao, and G.R. Gandhi Enhanced synthesis and reduced metabolism of endothelin-1 (ET-1) by hepatocytes-an important mechanism of increased endogenous levels of ET-1 in liver cirrhosis J. Hepatol. 33 2000 725 732
17. A. Leivas, W. Jimenez, S. Lamas, M. Bosch-Marce, J. Oriola, J. Claria, V. Arroyo, F. Rivera, and J. Rodes Endothelin-1 does not play a major role in the homeostasis of arterial pressure in cirrhotic rats with ascites Gastroenterology 108 1995 1842 1848
18. V.A. Luketic, and A.J. Sanyal The current status of ursodeoxycholate in the treatment of chronic cholestatic liver disease Gastroenterologist 2 1994 74 79
19. J. Ma, T. Nakajima, H. Iida, K. Iwasawa, K. Terasawa, H. Oonuma, T. Jo, T. Morita, H. Imuta, J. Suzuki, K. Hirose, Y. Okuda, N. Yamada, R. Nagai, and M. Omata Inhibitory effects of ursodeoxycholic acid on the induction of nitric oxide synthase in vascular smooth muscle cells Eur. J. Pharmacol. 464 2003 79 86
20. I. Makino, and H. Tanaka From a choleretic to an immunomodulator: historical review of ursodeoxycholic acid as a medicament J. Gastroenterol. Hepatol. 13 1998 659 664
21. P.A. Marsden, and B.M. Brenner Transcriptional regulation of the endothelin-1 gene by TNF-α Am. J. Physiol. 262 1992 C854 C861
22. N. Mitsutomi, C. Akashi, J. Odagiri, and Y. Matsumura Effects of endogeneous and exogeneous nitric oxide on endothelin-1 production in cultured vascular endothelial cells Eur. J. Pharmacol. 364 1999 65 73
23. H. Mitsuyoshi, T. Nakasima, Y. Sumida, T. Yoh, Y. Nakajima, H. Ishikawa, K. Inaba, Y. Sakamoto, T. Okanoue, and K. Kashima Ursodeoxycholic acid protects hepatopcytes against oxidative injury via induction of antioxidants Biochem. Biophys. Res. Commun. 24 1999 537 542
24. S. Moller, V. Gulberg, J.H. Henriksen, and A.L. Gerbes Endothelin-1 and endothelin-3 in cirrhosis: relations to systemic and splanchnic haemodynamics J. Hepatol. 23 1995 135 144
25. S. Moncada, R.M. Palmer, and E.A. Higgs Nitric oxide: physiology, pathophysiology, and pharmacology Pharmacol. Rev. 43 1991 109 142
26. 2+ concentration and nitric oxide production in vascular endothelial cells Br. J. Pharmacol. 130 2000 1457 1467
27. C. Nathan Nitric oxide as a secretory product of mammalian cells FASEB J. 6 1992 3051 3064
28. M. Pinzani, S. Milani, R. De Franco, C. Grappone, A. Caligiuri, A. Gentilini, C. Tosti-Guerra, M. Maggi, P. Failli, C. Ruocco, and P. Gentilini Endothelin-1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells Gastroenterology 110 1996 534 548
29. J.L. Poo, G. Feldmann, S. Erlinger, A. Braillon, C. Gaudin, M. Dumont, and D. Lebrec Ursodeoxycholic acid limits liver histologic alterations and portal hypertension induced by bile duct ligation in the rat Gastroenterology 102 1992 1752 1759
30. J.L. Poo, A. Estanes, J. Pedraza-Chaverri, C. Cruz, and M. Uribe Effects of ursodeoxycholic acid on hemodynamic and renal function abnormalities induced by obstructive jaundice in rats Ren. Fail. 17 1995 13 20
31. J. Reichen, A.L. Gerbes, M.J. Steiner, H. Sagesser, and M. Clozel The effect of endothelin and its antagonist Bosentan on hemodynamics and microvascular exchange in cirrhotic rat liver J. Hepatol. 28 1998 1020 1030
32. D.C. Rockey, and R.A. Weisiger Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance Hepatology 24 1996 233 240
33. D.C. Rockey, L. Fouassier, J.J. Chung, A. Carayon, P. Vallee, C. Rey, and C. Housset Cellular localization of endothelin-1 and increased production in liver injury in the rat: potential for autocrine and paracrine effects on stellate cells Hepatology 27 1998 472 480
34. G.M. Rubanyi, and M.A. Polokoff Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology Pharmacol. Rev. 46 1994 325 415
35. 2+ oscillation, and activation of glycogenolysis J. Clin. Invest. 87 1991 133 138
36. V. Shah Cellular and molecular basis of portal hypertension Clin. Liver Dis. 5 2001 629 644
37. P. Sogni, R. Moreau, A. Gomola, A. Cadano, S. Cailmail, Y. Calmus, M. Clozel, and D. Lebrec Beneficial hemodynamic effects of bosentan, a mixed ETA and ETB receptor antagonist, in portal hypertensive rats Hepatology 28 1998 655 659
38. A. Stiehl, G. Rudolph, R. Raedsch, B. Moller, U. Hopf, E. Lotterer, J. Bircher, U. Folsch, J. Klaus, and R. Endele Ursodeoxycholic acid-induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis Hepatology 12 1990 492 497
39. S. Tieche, A. De Gottardi, A. Kappeler, S. Shaw, H. Sagesser, A. Zimmermann, and J. Reichen Overexpression of endothelin-1 in bile duct ligated rats: correlation with activation of hepatic stellate cells and portal pressure J. Hepatol. 34 2001 38 45
40. Y.T. Tsai, H.C. Lin, M.C. Yang, F.Y. Lee, M.C. Hou, L.S. Chen, and S.D. Lee Plasma endothelin levels in patients with cirrhosis and their relationships to the severity of cirrhosis and renal function J. Hepatol. 23 1995 681 688
41. M. Yanagisawa, H. Kurihara, S. Kimura, Y. Tomobe, M. Kobayashi, Y. Mitsui, Y. Yazaki, K. Goto, and T. Masaki A novel potent vasoconstrictor peptide produced by vascular endothelial cells Nature 332 1988 411 415